Amgen Says Open Label Extension Trial Data Shows Efficacy of Repatha in HIV Patients With High Cholesterol
01:25 PM EDT, 05/11/2021 (MT Newswires) -- Amgen (AMGN) said Tuesday that data from an open label extension trial showed the safety and effectiveness of Repatha in HIV patients with high cholesterol.
According to the company, the final results of the open label extension period demonstrated that long-term administration of Repatha, or evolocumab, has a favorable benefit-risk profile in patients with HIV.
The recent data further confirm the safety and efficacy of Repatha across various high-risk patient populations in reducing cardiovascular events, the company said.
Repatha is for adults with established cardiovascular disease to aid in reducing the risk of myocardial infarction, stroke, and coronary revascularization.
Price: 253.40, Change: +0.78, Percent Change: +0.31